We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 07, 2022

Rogaratinib vs Chemotherapy for FGFR1/3 mRNA–Positive Locally Advanced or Metastatic Urothelial Carcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
J. Clin. Oncol 2022 Oct 14;[EPub Ahead of Print], CN Sternberg, DP Petrylak, J Bellmunt, H Nishiyama, A Necchi, H Gurney, JL Lee, MS van der Heijden, E Rosenbaum, N Penel, ST Pang, JR Li, X García Del Muro, F Joly, Z Pápai, W Bao, P Ellinghaus, C Lu, M Sierecki, S Coppieters, K Nakajima, TC Ishida, DI Quinn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading